ArticleFrontiers in pediatrics2023

Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children.

Liyuan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.